Comparative Pharmacology
Head-to-head clinical analysis: FABIOR versus TARGRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABIOR versus TARGRETIN.
FABIOR vs TARGRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), inducing differentiation and apoptosis of keratinocytes.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
FABIOR (tazarotene) foam, 0.1%: Apply a thin layer once daily in the evening to affected areas of the face, scalp, or trunk.
300 mg/m2 orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24-26 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Primarily hepatic metabolism via CYP450; renal excretion of metabolites accounts for <1% of dose as unchanged drug. Fecal elimination is the major route (approximately 90%).
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Category C
Category C
Retinoid
Retinoid